Wednesday, May 25, 2005 9:11:29 PM
Website: http://www.ablelabs.com/
INSTITUTIONAL HOLDERS & SHORT INTEREST: (just enter 'ABRX' and click 'GO')
http://lionshares.com/details.cfm?SEARCH=symbol&CUSIP=00371N407&SID=DSUD001%2081301460419103....
http://quotes.nasdaq.com/asp/MasterDataEntry.asp?page=Short%20Interest
Shares Outstanding: 17.95 million
Float: 16 million
Book Value: 4.964/share
http://finance.yahoo.com/q/ks?s=ABRX
REVENUE (ABLE LABS ONLY):..............EARNINGS PER SHARE (split-adjusted, fully diluted): .......(taken from SEC filings and press releases)
2000: 1.3 million.......................................2000: -1.80
2001: 16.5 million.....................................2001: -.525 (-1.50 including one-time, non-cash items)
2002: 52.9 million.....................................2002: +.63 (1.44 including one-time, non-cash items)
2003:
--Q1: 15.0 million.....................................--Q1: +.06
--Q2: 18.9 million.....................................--Q2: +.14
--Q3: 20.9 million.....................................--Q3: +.13
--Q4: 22.8 million.....................................--Q4: +.13
Total: 77.6 million.............................................+.46
2004:
--Q1: 21.5 million.....................................--Q1: +.10
--Q2: 23.0 million.....................................--Q2: +.11
--Q3: 27.3million......................................--Q3: +.23
--Q4: 31.4 million.....................................--Q4: +.32
Total: 103.2 million...........................................+.75
2005:
--Q1: 30.7 million.....................................--Q1: +.24
CURRENT PRODUCTS: http://www.ablelabs.com/products/products.html
ALL PRS SINCE NOVEMBER 2000: http://www.ablelabs.com/investors/pr.html
MANAGEMENT: http://www.ablelabs.com/about/management.html
RESEARCH & DEVELOPMENT: http://www.ablelabs.com/about/rd.html
SEC FILINGS (ABRX): http://www.pinksheets.com/quote/filings.jsp?symbol=ABRX
Primary Investor Contact
Able Laboratories Investor Relations
Andreea C. Cordoba
phone: 908.754.2253 ext 664
fax: 908.754.1736
IR@ablelabs.com
http://www.ablelabs.com/investors/investors.html
INDUSTRY LINKS AND ARTICLES:
Generic Vs. Brand Name Drugs: What's The Real Difference? http://www.healthcentral.com/drdean/deanfulltexttopics.cfm?id=35609
FDA Ensures Equivalence of Generic Drugs http://www.fda.gov/fdac/special/newdrug/generic.html
FDA New and Generic Drug Approvals By Name http://www.fda.gov/cder/approval/index.htm
International Journal of Generic Drugs http://www.locum.co.il/
Thanks.
Disclaimer: We have represented all information above as objectively and accurately as possible. Opinion, including our own, is contained in the above page. Please call Jay Wadekar at 908-754-2253 for clarificiation on any of the above information. Please do not buy or sell ABRX based on this post alone. You are responsible for doing your own due diligence to confirm any of the above and to assess any other available investor information.
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM